Patents Examined by Timothy R Rozof
  • Patent number: 11059787
    Abstract: The present invention provides a novel crystalline form of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide methanesulfonate (i.e., lenvatinib mesylate) and pharmaceutical compositions thereof. Methods of preparing such a crystalline form and uses in treatment are also provided.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: July 13, 2021
    Assignee: SHENZHEN BOLAN PHARMACEUTICAL CO., LTD
    Inventor: Xiangguang Xiao
  • Patent number: 11059784
    Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; R1 is —OH or —OP(O)(OH)2; L is —CR3?N—O—CRaRa— or CRaR—O—N?CR3; L2 is a bond, —C(O)—, or S(O)2—; and R2, R3, Ra, m, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: July 13, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, Ling Li, T. G. Murali Dhar, Hai-Yun Xiao
  • Patent number: 11058678
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: July 13, 2021
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joseph Panarese, Samuel Bartlett, Katherine Chong, Yat Sun Or
  • Patent number: 11058670
    Abstract: Methods and compositions are disclosed for diagnosing a patient suspected of suffering from, and for treating a patient suffering from, a disorder such as hypercortisolemia, metabolic syndrome, pre-diabetes, diabetes, Cushing's syndrome, Cushing's Disease, hyperglycemia secondary to hypercortisolemia, a liver disease, a cardiac disorder, high blood pressure, a blood clotting disorder, a cancer, a psychological disorder, weight gain, a disorder of glucose control, a bone disorder (e.g., osteoporosis), hypogonadism, pseudoacromegaly, pituitary tumors, functional hypercortisolism, ACTH secreting tumors, peripheral neuropathy, dyslipidemia and other disorders. The methods and compositions include administration of a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (GRM).
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: July 13, 2021
    Assignee: Corcept Therapeutics Incorporated
    Inventor: Andreas Moraitis
  • Patent number: 11040009
    Abstract: This disclosure relates to polymersomes comprising a crosslinked polymer and their use as drug delivery vehicles. Specifically, polymersomes comprising a polymer of Formula I: wherein each R is independently C1-6 alkyl; and n is an integer between 1 and 50.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: June 22, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Xifeng Liu, Michael J. Yaszemski, Lichun Lu
  • Patent number: 11040950
    Abstract: In a method and an apparatus furfural is recovered from a steam stream (3) which is formed in a treatment of a pretreated wood based material (1). The pretreated wood based material (1) which comprises at least carbohydrates is treated in a steam treatment stage (2) in which the steam is released. The steam stream (3) which comprises furfural is supplied out from the steam treatment stage (2). A pretreated and steam-treated wood based material (4) which comprises carbohydrates is supplied out from the steam treatment stage (2), and the steam stream (3) is treated in a recovery stage (12a, 12b) for recovering a furfural based fraction (14a,14b).
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: June 22, 2021
    Assignee: UPM-KYMMENE CORPORATION
    Inventors: Juha Tamper, Jere Salminen, Mauno Miettinen, Sami Turunen, Meri Ventola, Vilho Nissinen
  • Patent number: 11040028
    Abstract: Provided are penicinotam derivatives, a tautomer, a stereoisomer, a racemate, a nonequal mixture of enantiomers, a geometric isomer, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceutical composition comprising the derivatives. Also provided herein is use of the derivatives and the pharmaceutical compositions in treating diseases caused by inflammation, immune system disorders.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: June 22, 2021
    Assignee: OCEAN UNIVERSITY OF CHINA
    Inventors: Changlun Shao, Meiyan Wei, Yaoyao Jiang
  • Patent number: 11040027
    Abstract: The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: June 22, 2021
    Assignee: Heparegenix GMBH
    Inventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke
  • Patent number: 11034656
    Abstract: The present application relates to maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)aniline]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, crystalline forms thereof, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 15, 2021
    Assignee: Teligene Ltd.
    Inventor: Dawei Zhang
  • Patent number: 11034710
    Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: June 15, 2021
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Yuji Fujiwara, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
  • Patent number: 11028050
    Abstract: Provided herein are free base crystalline forms and crystalline salts of Compound 1.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: June 8, 2021
    Assignee: TETRA DISCOVERY PARTNERS, INC.
    Inventors: Mark E. Gurney, Jon P. Lawson, Stephan D. Parent, Richard James Ely
  • Patent number: 11021445
    Abstract: The present invention relates to a compound shown in formula (II) or a pharmaceutically acceptable salt thereof and an application of the same in preparing a drug for treating a disease related to angiotensin II receptor type 2 (AT2R).
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: June 1, 2021
    Inventors: Yang Zhang, Wentao Wu, Zhixiang Li, Mingxing Teng, Guangwen Yang, Jie Li, Jian Li, Shuhui Chen
  • Patent number: 11014934
    Abstract: The invention refers to the chemistry of organic heterocyclic compounds, namely the new quaternary ammonium salt containing a fragment of vitamin B6 derivative of formula I, showing antibacterial, antimycotic, antiviral and antiprotozoic properties. Compound can be used in medicine and veterinary medicine. The invention can be used in medicine and veterinary medicine.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: May 25, 2021
    Assignees: AO “Tatkhimfarpreparaty”, Kazan Federal University
    Inventors: Yurij G. Shtyrlin, Nikita V. Shtyrlin, Aleksej D. Strel'nik, Sergej V. Sapozhnikov, Al'fiya G. Iksanova, Renata R. Kazakova, Mariya N. Agafonova
  • Patent number: 11014888
    Abstract: A crystalline form of alkynyl pyridine prolyl hydroxylase inhibitor and a method for preparing same are described. Specifically, a new crystalline form of alkynyl pyridine prolyl hydroxylase inhibitor as represented by formula (I) is described. The new crystalline form of the present invention has good stability and may be better used for clinical treatment.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: May 25, 2021
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Lijuan Zhai, Zhenxing Du, Likun Wang
  • Patent number: 11014921
    Abstract: The invention provides a compound of formula I: or a salt thereof, wherein R1, R2, and R3 have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as immunomodulating agents.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: May 25, 2021
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Sunil A. David, Janardhan Banothu, Mallesh Beesu, Michael Brush
  • Patent number: 11008299
    Abstract: The present invention relates to the synthesis of intermediate compounds which can be used in the synthesis of mint lactone and related compounds, including 3,6-dimethylhexahydrobenzofuran-2-ones, isomers, and other derivatives.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: May 18, 2021
    Assignee: P2 SCIENCE, INC.
    Inventors: Patrick Foley, Yonghua Yang, Tania Salam
  • Patent number: 10995090
    Abstract: Compounds of formula (I), wherein R?, R?, R, X, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: May 4, 2021
    Assignee: Asceneuron SA
    Inventors: Anna Quattropani, Santosh S. Kulkarni, Awadut Gajendra Giri
  • Patent number: 10988483
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 27, 2021
    Assignee: NFlection Therapeutics, Inc.
    Inventors: John Kincaid, Matthew Duncton
  • Patent number: 10988486
    Abstract: The present specification relates to a compound containing nitrogen, and a color conversion film, a backlight unit, and a display device, including the same.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: April 27, 2021
    Assignee: LG CHEM, LTD.
    Inventors: Hye Mi Oh, Seijung Park, Dong Mok Shin
  • Patent number: 10980789
    Abstract: A therapeutic agent for fibrosis, whose active ingredient is constituted by a glucosylceramide synthase inhibitor or lactosylceramide synthase inhibitor, or both, inhibits the nuclear translocation of phosphorylated Smad, thereby treating and preventing fibrosis.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: April 20, 2021
    Assignee: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
    Inventors: Hiroyuki Nakamura, Toshihiko Murayama